# Serplulimab Combined With Cryoablation for Early-Stage Non-Small Cell Lung Cancer

> **NCT07064876** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Xi Junjie** · enrollment: 25 (estimated)

## Conditions studied

- Early Lung Cancer

## Interventions

- **DRUG:** Serplulimab
- **PROCEDURE:** CT-guided Cryoablation

## Key facts

- **NCT ID:** NCT07064876
- **Lead sponsor:** Xi Junjie
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10
- **Primary completion:** 2026-10
- **Final completion:** 2027-09
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07064876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07064876, "Serplulimab Combined With Cryoablation for Early-Stage Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07064876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*